Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara) earlier in the treatment algorithm. Additionally, the availability of Pfizer’s Xeljanz / Xeljanz XR, Bristol Myers Squibb’s Zeposia, and Gilead / Galapagos’s Jyseleca have expanded physicians’ treatment armamentarium and intensified market competition. Furthermore, the recent approvals of Eli Lilly’s Omvoh (in the United States, Europe and Japan), Pfizer’s Velsipity (in the United States and Europe), and AbbVie’s Rinvoq (in the United States and Europe) and the expected launch of several therapies with novel mechanisms of action (e.g., AbbVie’s Skyrizi, Johnson & Johnson Innovative Medicine’s Tremfya, ABX464) will drive market growth. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars.


  • What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
  • How do gastroenterologists perceive biosimilar agents, and what has been/will be their impact on the UC market?
  • What are key opinion leaders’ (KOLs’) insights into the current treatment options for TNF-refractory UC (e.g., Xeljanz / Xeljanz XR, Entyvio, Stelara, Rinvoq, Zeposia, Jyseleca)? What factors drive their treatment decisions?
  • What are KOLs’ perceptions of recently approved / key emerging therapies (e.g., Skyrizi, Tremfya, Velsipity, Omvoh), and where do they see these agents fitting into the treatment algorithm?


Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 22 country-specific interviews with thought-leading gastroenterologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of UC by country, segmented by disease activity.

Forecast: Ten-year, annualized, drug-level sales and patient share of key UC therapies through 2032, segmented by brands / generics / biosimilars, and acute and maintenance settings.

Emerging therapies: Phase 3 / preregistered: ~7 drugs; coverage of select early-phase products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports